General
AstraZeneca COVID-19 vaccine faces regulatory hurdles as Novavax releases both ‘encouraging’ and ‘concerning’ results
Experts say the problems associated with “first-generation” COVID-19 vaccines are being exposed, as one European regulatory body questions the lack of data supplied for the Oxford-AstraZeneca vaccine and recommending against its use for the elderly.
Key points:
- European regulatory bodies are concerned over the lack of data for the elderly during trials of the Oxford-AstraZeneca vaccine
- The TGA, described as “the best regulator in the world” by the Health Minister, is expected to make a decision in February
- It comes as Novavax, the third vaccine the Australian Government has committed to purchasing, released “encouraging” interim results
On Friday, Germany’s vaccine committee recommended the Oxford-AstraZeneca vaccine — of which…
Continue Reading
-
Business14 hours ago5 things to watch on the ASX 200 on Thursday 4 September 2025
-
Noosa News10 hours agoDog owners warned: $834 fine for pets not under control
-
Business16 hours agoA perfect 4.5% dividend stock paying cash every month in a volatile market
-
Noosa News12 hours agoPharmacist’s stolen image used in ‘dangerous’ deepfake adverts for weight loss drug